A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Parallel-Group Study to Assess the Safety and Tolerability of Ragweed-SPIRE in Subjects With Asthma and Ragweed-Induced Rhinoconjunctivitis

Trial Profile

A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Parallel-Group Study to Assess the Safety and Tolerability of Ragweed-SPIRE in Subjects With Asthma and Ragweed-Induced Rhinoconjunctivitis

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2015

At a glance

  • Drugs Ragweed SPIRE (Primary)
  • Indications Allergic rhinoconjunctivitis; Asthma; Ragweed pollen hypersensitivity
  • Focus Adverse reactions
  • Sponsors Circassia
  • Most Recent Events

    • 20 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 25 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top